Multiple SclerosisVR-OKS-MSNCT07150520
VR-Based Optokinetic Stimulation in Multiple Sclerosis
A study testing Virtual Reality-Based Optokinetic Stimulation (OKS) in people with Multiple Sclerosis, run by Avrasya University.
Trial summary
The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS) Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- Virtual Reality-Based Optokinetic Stimulation (OKS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2025to Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be an adult aged 18-55 years
- Have a confirmed diagnosis of MS by a neurologist (for MS groups)
- Not have had a relapse in the last 3 months (for MS patients)
- Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
- Be a healthy control with no condition preventing participation
Who cannot join
- Have peripheral vestibular dysfunction (for MS groups)
- Be older than 55 years
- Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
- Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)
About this study
Official title: Acute Effects of Virtual Reality-Based Optokinetic Stimulation in Individuals With Multiple Sclerosis: Does Central Vestibular Dysfunction Alter These Effects?
The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS)
Read the detailed description
This study will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. It will investigate the acute effects of virtual reality-based optokinetic stimulation (OKS) on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS). Participants will include MS patients with and without central vestibular dysfunction, as well as age- and sex-matched healthy controls. MS participants will first undergo vestibular function assessment using videonystagmography (VNG). Postural control will then be measured via a force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute OKS session using Oculus Quest 2. Healthy participants will follow the same postural and OKS assessment protocol without VNG.Motion sickness and virtual reality effects will be evaluated using the Simulator Sickness Questionnaire. Data will be analyzed using appropriate parametric or non-parametric tests to compare postural sway and VR-related symptoms across groups, with significance set at p < 0.05.
- Conditions
- Multiple Sclerosis
- Being tested
- Virtual Reality-Based Optokinetic Stimulation (OKS)
- Keywords
- multiple sclerosis, vestibular dysfunction, optokinetic stimulation, virtual reality
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Reality-Based Optokinetic Stimulation (OKS)Device
A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
| Study group | Role | What they receive |
|---|---|---|
| MS with Central Vestibular Dysfunction | Experimental | Participants with multiple sclerosis who have central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention. Receives: Device: Virtual Reality-Based Optokinetic Stimulation (OKS) |
| MS without Central Vestibular Dysfunction | Experimental | Participants with multiple sclerosis without central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention. Receives: Device: Virtual Reality-Based Optokinetic Stimulation (OKS) |
| Healthy Controls | Experimental | Healthy participants will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention Receives: Device: Virtual Reality-Based Optokinetic Stimulation (OKS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postural Sway
Postural sway will be assessed using the FreeMED force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute virtual reality-based optokinetic stimulation (OKS) session. Parameters include sway path, mediolateral (delta X), and anteroposterior (delta Y) displacement.
Measured: Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2025
- Study start15 Sep 2025 (estimated)
- Primary completionOct 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- All participants will receive the same virtual reality-based optokinetic stimulation protocol. Comparisons will be made between MS patients with and without central vestibular dysfunction and healthy controls
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Avrasya University
- Sponsor type
- University, hospital or other
- Collaborators
- Hacettepe University
- Responsible party
- Principal investigator, Özge Özdemir, Avrasya University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07150520
- Sponsor's protocol ID
- 2025/102
- Acronym
- VR-OKS-MS
- Status last verified
- Sep 2025
- First submitted
- 25 Aug 2025
- Last updated
- 9 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Effects of Virtual Reality-Based Optokinetic Stimulation in Individuals With Multiple Sclerosis: Does Central Vestibular Dysfunction Alter These Effects?
- ClinicalTrials.gov ID
- NCT07150520
- Acronym / sponsor ID
- VR-OKS-MS / 2025/102
- Conditions
- Multiple Sclerosis
- Keywords
- multiple sclerosis, vestibular dysfunction, optokinetic stimulation, virtual reality
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Avrasya UniversityUniversity, hospital or other
- Collaborators
- Hacettepe University
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 2 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS)
Detailed description
This study will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. It will investigate the acute effects of virtual reality-based optokinetic stimulation (OKS) on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS). Participants will include MS patients with and without central vestibular dysfunction, as well as age- and sex-matched healthy controls. MS participants will first undergo vestibular function assessment using videonystagmography (VNG). Postural control will then be measured via a force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute OKS session using Oculus Quest 2. Healthy participants will follow the same postural and OKS assessment protocol without VNG.Motion sickness and virtual reality effects will be evaluated using the Simulator Sickness Questionnaire. Data will be analyzed using appropriate parametric or non-parametric tests to compare postural sway and VR-related symptoms across groups, with significance set at p < 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- All participants will receive the same virtual reality-based optokinetic stimulation protocol. Comparisons will be made between MS patients with and without central vestibular dysfunction and healthy controls
| Arm | Type | Receives |
|---|---|---|
| MS with Central Vestibular Dysfunction | Experimental | Device: Virtual Reality-Based Optokinetic Stimulation (OKS)Participants with multiple sclerosis who have central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention. |
| MS without Central Vestibular Dysfunction | Experimental | Device: Virtual Reality-Based Optokinetic Stimulation (OKS)Participants with multiple sclerosis without central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention. |
| Healthy Controls | Experimental | Device: Virtual Reality-Based Optokinetic Stimulation (OKS)Healthy participants will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Be an adult aged 18-55 years
- Have a confirmed diagnosis of MS by a neurologist (for MS groups)
- Not have had a relapse in the last 3 months (for MS patients)
- Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
- Be a healthy control with no condition preventing participation
Key exclusion criteria (4 listed)
- Have peripheral vestibular dysfunction (for MS groups)
- Be older than 55 years
- Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
- Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Reality-Based Optokinetic Stimulation (OKS)A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention. | Device | Healthy Controls, MS with Central Vestibular Dysfunction, MS without Central Vestibular Dysfunction |
Primary outcome
Postural Sway
Time frame: Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session
Postural sway will be assessed using the FreeMED force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute virtual reality-based optokinetic stimulation (OKS) session. Parameters include sway path, mediolateral (delta X), and anteroposterior (delta Y) displacement.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Active, not recruiting
Tai Chi Training for Persons With Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Reality-Based Optokinetic Stimulation (OKS) in people with Multiple Sclerosis, run by Avrasya University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postural Sway (time frame: Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2025.